Clinical Trial Detail

NCT ID NCT01744340
Title A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors howard safran
Indications

head and neck squamous cell carcinoma

Therapies

Eribulin

Cetuximab

Age Groups: adult

No variant requirements are available.